慢病毒与基因组编辑策略治疗β-血红蛋白病
β-地中海贫血和镰状细胞病是最常见的单基因病,由成人血红蛋白生成的数量或质量缺陷所致。携带β-珠蛋白样基因的新一代慢病毒载体(LV)可实现有效造血干细胞转导,迄今未发现基因毒性证据。全球多项不同载体类型的临床试验正在进行,初步结果显示治疗性血红蛋白持续产生、生物学参数改善、输血需求降低和生活质量提高。
要点
- 携带β-珠蛋白样基因的LV可实现有效HSC转导,迄今无基因毒性证据。
- 多项LV基因添加临床试验初步结果:治疗性血红蛋白持续产生、输血需求降低。
- 优化预处理、HSC采集和转导进一步提升了该方法的治疗潜力。
核心结论
- LV基因添加治疗β-血红蛋白病初步结果鼓励,长期随访将确认安全性。
- 再激活HbF的新LV策略及基因组编辑方法是有前景的替代治疗策略。
研究设计与样本
- 综述讨论当前LV基因添加临床试验的临床结果及新型替代治疗策略。
主要发现
- LV基因添加临床试验初步结果显示治疗性血红蛋白持续产生、生物学参数改善、输血需求降低、生活质量提高。
- 优化患者预处理、HSC采集和HSC转导进一步改善了该方法的治疗潜力。
- 升高HbF水平可降低β-地中海贫血和SCD的严重程度。
- 基因组编辑方法旨在纠正致病突变或再激活HbF,目前正在研究中。
临床怎么用
- 基因治疗是缺乏全相合HSC供者的患者的潜在治疗选择。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
β-Thalassemia and sickle cell disease (SCD) are the most prevalent monogenic diseases. These disorders are caused by quantitative or qualitative defects in the production of adult hemoglobin. Gene therapy is a potential treatment option for patients lacking an allogenic compatible hematopoietic stem cell (HSC) donor. New-generation lentiviral vectors (LVs) carrying a β-globin-like gene have revolutionized this field by allowing effective HSC transduction, with no evidence of genotoxicity to date. Several clinical trials with different types of vector are underway worldwide; the initial results are encouraging with regard to the sustained production of therapeutic hemoglobin, improved biological parameters, a lower transfusion requirement, and better quality of life. Long-term follow-up studies will confirm the safety of LV-based gene therapy. The optimization of patient conditioning, HSC harvesting, and HSC transduction has further improved the therapeutic potential of this approach. Novel LV-based strategies for reactivating endogenous fetal hemoglobin (HbF) are also promising, because elevated HbF levels can reduce the severity of both β-thalassemia and SCD. Lastly, genome-editing approaches designed to correct the disease-causing mutation or reactivate HbF are currently under investigation. Here, we discuss the clinical outcomes of current LV-based gene addition trials and the promising advantages of novel alternative therapeutic strategies.
引用
- Magrin E, Miccio A, Cavazzana M, et al. Lentiviral and genome-editing strategies for the treatment of β-hemoglobinopathies. Blood. 2019. PMID: 31467062. doi:10.1182/blood.2019000949
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。